A new trading day began on Tuesday, with Century Therapeutics Inc (NASDAQ: IPSC) stock price down -3.58% from the previous day of trading, before settling in for the closing price of $0.6. IPSC’s price has ranged from $0.34 to $3.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 18.46%. Meanwhile, its annual earnings per share averaged 82.97%. With a float of $40.60 million, this company’s outstanding shares have now reached $86.15 million.
The extent of productivity of a business whose workforce counts for 150 workers is very important to gauge. In terms of profitability, gross margin is 100.0%, operating margin of -28.42%, and the pretax margin is -17.54%.
Century Therapeutics Inc (IPSC) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Century Therapeutics Inc is 52.88%, while institutional ownership is 28.81%. The most recent insider transaction that took place on Jun 09 ’25, was worth 3,050. In this transaction SVP Finance & Operations of this company sold 4,904 shares at a rate of $0.62, taking the stock ownership to the 405,982 shares. Before that another transaction happened on Jun 09 ’25, when Company’s Chief Operations Officer sold 552 for $0.62, making the entire transaction worth $343. This insider now owns 250,141 shares in total.
Century Therapeutics Inc (IPSC) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 82.97% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.86% during the next five years compared to 18.46% growth over the previous five years of trading.
Century Therapeutics Inc (NASDAQ: IPSC) Trading Performance Indicators
Here are Century Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 11.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.28, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Century Therapeutics Inc (IPSC)
The latest stats from [Century Therapeutics Inc, IPSC] show that its last 5-days average volume of 1.11 million was superior to 0.69 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 52.94%.
During the past 100 days, Century Therapeutics Inc’s (IPSC) raw stochastic average was set at 49.73%, which indicates a significant increase from 48.42% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0368 in the past 14 days, which was lower than the 0.0442 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5666, while its 200-day Moving Average is $0.8881. Now, the first resistance to watch is $0.6047. This is followed by the second major resistance level at $0.6310. The third major resistance level sits at $0.6520. If the price goes on to break the first support level at $0.5574, it is likely to go to the next support level at $0.5364. The third support level lies at $0.5101 if the price breaches the second support level.
Century Therapeutics Inc (NASDAQ: IPSC) Key Stats
With a market capitalization of 49.83 million, the company has a total of 86,159K Shares Outstanding. Currently, annual sales are 6,590 K while annual income is -126,570 K. The company’s previous quarter sales were 109,160 K while its latest quarter income was 76,560 K.
